English Product Description
Finax 1mg Tablets contain Finasteride 1mg. Finasteride is a prescription medicine used for the treatment of male pattern hair loss, also known as androgenetic alopecia. It is for men only and should not be used by women or children.
Finasteride works by reducing the level of dihydrotestosterone, or DHT, a hormone associated with shrinking hair follicles in male pattern hair loss. By lowering DHT levels, Finasteride may help slow hair loss and support hair regrowth in men.
Dosage and Use
Take one tablet once daily, or as directed by your doctor. It may be taken with or without food. Daily use for at least 3 months is usually needed before benefit may be seen. Continued use is required to maintain the effect. If treatment is stopped, the benefit may gradually be lost.
Do not take more than one tablet per day. Taking more will not make the medicine work faster or better.
Who Should Not Use This Medicine
Do not use this medicine if you are allergic to Finasteride or any ingredient in the tablet. Women who are pregnant or may become pregnant should not use Finasteride and should not handle crushed or broken tablets, as it may harm a male unborn baby.
Warnings
Tell your doctor before taking Finasteride if you have prostate problems, liver problems, or if you are taking any other medicines. Finasteride can affect PSA blood test results used for prostate screening, so you should tell your doctor that you are taking it.
Possible Side Effects
Common side effects may include decreased sex drive, difficulty getting or maintaining an erection, and reduced semen amount. Other reported effects include breast tenderness or enlargement, testicular pain, allergic reactions such as rash or swelling, depression, ejaculation problems, poor semen quality, and rare cases of male breast cancer.
Some sexual side effects have been reported to continue after stopping treatment. Contact your doctor if any side effect bothers you or does not go away.
Storage
Store at room temperature, between 15°C and 30°C. Keep the tablets dry, in a closed container, and out of reach of children.
Sources: FDA Propecia / Finasteride 1mg label lines on use, dosage, warnings, side effects, and storage.
Dr. Reddy’s was established in 1984. After 23 years of development, the company’s revenue exceeded US$1 billion in 2007. With operations around the world, it has become an international enterprise. Since 2002, Dr. Reddy’s overseas business revenue has exceeded its domestic revenue, and its operating profit has continued to grow. In 2007, its revenue and profit margin ranked among the highest in India’s pharmaceutical industry.
Dr. Reddy’s Laboratories is the main subject here. In July 2006, it signed an agreement with Merck to manufacture and sell generic versions of Propecia.
The impact of Indian generic pharmaceutical companies on major European and American drug manufacturers is not only that they share market profits, but also that they have made these major companies realize the importance of lowering manufacturing costs and improving productivity. As a result, many have sought cooperation with Indian generic drug manufacturers.
Previously, the Indian government did not grant patents for pharmaceutical products. However, in 2005, India amended its patent law to provide patent protection for medicines, which also accelerated cooperation between multinational European and American pharmaceutical companies and Indian companies.
For example, Dr. Reddy’s obtained authorization from Merck and signed agreements before the U.S. patents of certain drugs expired, allowing it to manufacture and sell generic versions of medicines including Simvastatin, also known as Zocor, which is used to lower cholesterol and triglycerides, as well as the well-known Proscar for benign prostatic hyperplasia and Propecia for male pattern baldness.
At this point, is there still reason to doubt medicines produced by Indian generic pharmaceutical companies? Any remaining doubts were made difficult to sustain after the U.S. Food and Drug Administration, the FDA, approved the effectiveness of these generic medicines in July 2006.
